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Abstract Cancer stem cell (CSC) markers could serve as po-
tential prognostic procedure. This study is aimed to investi-
gate the local expression of doublecortin-like kinase 1
(DCLK1) and Lgr5 in colorectal cancer tissues (CRC) at both
protein and messenger RNA (mRNA) level, followed by pro-
viding a comparison of the local and circulating expression
pattern of these markers, based on our present and previous
study. The mRNA expression level of DCLK1 and Lgr5 was
evaluated using comparative real-time PCR method applying
58 fresh tumor tissues and their correspondent normal mar-
gins. Immunohistochemistry was applied to analyze the pro-
tein expression level of DCLK1 and Lgr5 in paraffin-
embedded CRC tissues. The correlation of DCLK1 and
Lgr5 expression pattern with clinicopathological characteris-
tics was assessed. A higher mRNA expression level of
DCLK1 (3.28-fold change, p<0.001) and Lgr5 (2.29-fold
change, p<0.001) was observed in CRC fresh tissues com-
pared to the normal adjacent margins, and the expression level
was higher in patients with higher grade and stages of disease
and patients who underwent neoadjuvant chemoradiotherapy
(CRT). The protein expression level of DCLK1 and Lgr5 was
also increased significantly in tumor tissues compared to nor-
mal colon tissues which were positively correlated to tumor
stage and grade and neoadjuvant CRT. Taken together, the
results of protein analysis were in accordance with mRNA
assessment. The local expression pattern of DCLK1 and
Lgr5 was also in accordance with their expression level in
circulation. However, some minor inconsistencies were ob-
served which may be attributed to several factors including
the possible effect of CRT on CSC reprogramming.
Keywords Colorectal cancer . DCLK1 . Lgr5 . Local cancer
stem cell . Circulating cancer stem cell
Introduction
A growing body of evidence supports the hypothesis that tu-
mors are initiated from a subpopulation of tumor cells named
Bcancer stem cell^ (CSC) [1–7]. Recently, CSC hypothesis has
attracted much attention in both cancer management and ther-
apy [8–11]. The acceptance of CSCs as the main players of
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tumor formation, survival, metastasis, resistance to treatment,
and recurrence imposes a new perspective to profit CSCs. In
this regard, reevaluation of tumor management focusing on
CSCs as tumor root instead of tumor-differentiated cells as
the tumor foliage should be taken into consideration [12].
Despite the significance of CSC hypothesis, application of
CSC to clinical implications has faced many difficulties.
Among them, similarity of CSC markers to normal stem cell
markers [13] and the heterogeneity of CSC markers [14, 15]
are considered as the most prominent drawbacks.
Doublecortin-like kinase (DCLK1) and Lgr5 are considered
as the most potential colorectal CSCmarkers, and their role has
been demonstrated in several studies [16–21]. Diagnostic and
prognostic role of DCLK1 and Lgr5 has also been shown in
blood circulation of colorectal cancer (CRC) patients, indicat-
ing traceability of circulating CSCs [22, 23]. The potentiality of
DCLK1 as a colorectal CSC marker has become even more
prominent following the study of Nakanishi et al. which have
used lineage tracing to show that DCLK1 does not mark nor-
mal intestinal stem cells but insteadmarks intestinal tumor stem
cells. Accordingly, it generates new hope in specific targeting
of CSC without damaging normal stem cell pool [24]. They
also showed that Lgr5 is co-expressed with DCLK1 on colo-
rectal CSCs as well as normal intestinal stem cells.
However, a question might be raised regarding whether
there is a difference in expression pattern of CSC markers in
tumor tissue, known as local CSC markers (LCSC), and CSC
markers in the peripheral blood (PB) of the patients, known as
circulating CSC (CCSC) markers. In spite of CSC markers’
diagnostic and prognostic significance, no study has been per-
formed in order to compare the expression pattern of local
CSC markers with the expression pattern of circulating CSC
markers. Therefore, we have designed a connected set of stud-
ies concerning diagnostic and prognostic potential of DCLK1
and Lgr5 as highly proposed colorectal CSC markers. In the
first part of the study, we investigated the DCLK1 and Lgr5
messenger RNA (mRNA) expression pattern in blood circu-
lation of CRC patients [22]. In the current study, the local
mRNA expression of DCLK1 and Lgr5 was evaluated in tu-
mor tissues of the same CRC patients. Finally, the results of
local expression of DCLK1 and Lgr5 from the current study
were compared with our previous data regarding the expres-
sion level of these markers in circulation. Application of blood
and tissue samples of the same patients made the results of the
current study completely comparable with our former study.
This comparison can be considered as a piece of CSC puzzle
which may pave the way for future investigations and provide
prerequisite information on the prognostic potentiality of
DCLK1 and Lgr5 markers in colorectal cancer. To our knowl-
edge, this is the first study comparing the local and circulating
cancer stem cell markers’ expression pattern.
Since proteins are the final product of the genes and mRNA
expression does not necessarily accord with protein
expression, comparison of mRNA and protein expression of
the markers may also result in valuable information.
Therefore, the protein expression of DCLK1 and Lgr5 was
also examined in the paraffin-embedded sections of the same
series of CRC patients using immunohistochemistry to en-
quire CSC markers’ protein and mRNA conformity.
Material and methods
Patients and samples
Since the beginning of 2013, in a prospective study, the blood
and fresh tissue samples of the CRC patients referred to Imam
Khomeini Hospital of Tehran University of Medical Sciences
were collected. The collection included 78 blood samples and
62 fresh tumor tissues. Fresh CRC tissue samples as well as
paired normal margins were obtained immediately after sur-
gery and kept on liquid nitrogen prior to be stored at −80 °C
freezer. Paraffin-embedded tissue and correspondent H&E
slides of the same patients were also acquired. Since the pur-
pose of the study was to compare the circulating and local
expression pattern of the markers, those samples in which
their blood, fresh, or paraffin-embedded tissue were missing
have been excluded from the study. Finally, a total of 58 pa-
tients in which their blood, fresh, and paraffin-embedded tis-
sue were available were included in the study. The circulating
mRNA expression of DCLK1 and Lgr5 in blood samples of
CRC patients has been previously examined [22], while the
local mRNA expression of these markers in tissue samples of
CRC patients was investigated in the present study. Totally, 34
patients with colon and 24 patients with rectum cancer were
enrolled in the study. Male patients comprised 53.5 % of the
study population, versus 46.5 % of female patients. The me-
dian patients’ age was 74.2 years, ranging from 28 to 86 years.
Tumors were staged and graded according to TNM classifica-
tion protocol [25]. Altogether, 11 patients with stages I and II,
28 patients with stage III, and 19 patients with stage IV of
colorectal adenocarcinoma were classified.
Considering the positive effect of preoperative chemora-
diotherapy (CRT) on tumor management and morbidity re-
duction in locally advanced tumors [26, 27], neoadjuvant
CRT was applied for stages II to IV of the disease according
to the protocol proposed by German rectal cancer study group
[27]. The main neoadjuvant chemotherapy regimen included
an intravenously infusion of a dose of 1000 mg/m2/day of 5-
fluorouracil (5-FU) throughout the first and fifth weeks of
radiotherapy. Preoperative radiotherapy included the adminis-
tration of a total dose of 50 GY which was given in 25 frac-
tions through 5 weeks. A number of 33 qualified patients
received preoperatively CRT treatment. The patients’ clinical
characteristics are shown in details in.
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This study was performed under the supervision and ap-
proval of the Ethics Committee of clinical investigation of
Tehran University of Medical Sciences, and written consents
were obtained from all participant patients.
RNA extraction, cDNA synthesis, and primer design
A total of 0.5 g of resected tissue samples was preprocessed and
homogenized using liquid nitrogen. Afterward, 200 μg of pro-
teinase Kwas added to each homogenized sample and incubated
at 37 °C for 1 h in order to digest unwanted proteins. Following
RNA extraction using TRIzol reagent and DNase treatment of
extracted RNA, complementary DNA (cDNA) was synthesized
using Revert Aid First-Strand cDNA Synthesis Kit according to
the company instructions (Thermo Scientific, USA). Real-time
PCR was performed applying SYBR® Premix Ex Taw™ II
(Takara, Japan). Beta-actin was selected as the reference gene
of choice, and its primers were purchased from Qiagen
Company (Hs_Actb_1_SG, QuantiTect Primer Assay
QT00095431, Qiagen, USA). Lgr5 and DCLK1 primer sets
were designed with AlleleID 6.0 software and were synthesized
by Metabion Company (Germany) [22]. Their sequences are as
follows: DCLK1 F: AGGGTCGTAA ACTGGTGGGA AAC,
DCLK1 R: TGTCTGTATG GGCAAGATAT GGTAAAC and
Lgr5 F: CTGAACTAAG AACACTGACT CTGAATG, Lgr5
R: CACTTGGAGATTAGGTAACT GATTGC.
Real-time PCR
Real-time PCR was performed using a StepOnePlusTM Real-
Time PCR System (Applied Biosystems, USA) for 1 cycle at
95 °C for 2 min followed by 40 cycles at 95 °C for 5 s and
60 °C for 30 s. Specificity of the products was approved by
melting curve analysis, and positive and negative controls
were included in each run. Data was analyzed according to
comparative Ct method [28]. 2−ΔCt whereΔCt=(CT of target
gene−CTof internal control) was calculated in order to obtain
mean ± SD of each sample mRNA expression for further
statistical analysis. Considering the basic assumption of com-
parative Ct method which is the approximately equal amplifi-
cation efficiency of target and reference genes, average effi-
ciency of each genewas calculated using real-time PCRMiner
system [29]. Comparable efficiency ofβ-actin (95.7), DCLK1
(94.8), and Lgr5 (96.6) approved the comparative Ct method
for quantitative evaluation of DCLK1 and Lgr5mRNA levels.
Tissue microarray
The tissue microarrays (TMA) were constructed as described
in our previous studies [30–32]. To this aim, four different
tumor regions were marked on each H&E slides, and the
marked regions was transferred into their correspondent
paraffin-embedded tissue blocks. Subsequently, from each
marked region on the donor blocks, a microarray sample with
the diameter of 0.6 mmwere punctuated and precisely arrayed
into a new recipient paraffin block using Tissue Arrayer
Minicore (ALPHELYS, Plaisir, France). Totally, four copies
of TMA block was constructed, each containing one sample
from different regions of the same paraffin-embedded block.
The mean scoring of the four cores was calculated as the final
score.
Immunohistochemical staining
Immunohistochemistry was performed on a 4-μm tissue sec-
tions using rabbit polyclonal anti-DCLK1 (Abcam, UK,
ab37994) and anti-Lgr5 (Abcam, UK, ab71225) as primary
antibodies.
Briefly, following deparaffinization and then rehydration of
slides, TMA sections were immersed in methanol containing
0.3 % hydrogen peroxide for 20 min to block possible endog-
enous peroxidase activity. Afterward, antigen retrieval process
was performed using autoclaving the section in citrate buffer
(pH=6) for 10 min. Sections were then incubated with prima-
ry antibodies with optimal dilutions which were found to be 1/
200 for DCLK1 and 1/400 for Lgr5 for 2 h at room tempera-
ture. Sections were then incubated with secondary antibody
(Envision System, Dako, Denmark) for 1 h at room tempera-
ture and after that were treated with 3,3′-diaminobenzidine
(DAB, Dako) in order to visualize antigen/antibody reaction.
Finally, counterstain was performed using hematoxylin
(Dako), and after dehydration steps, the slides were mounted
to be analyzed. The primary antibody was omitted from neg-
ative control slides and replaced with washing buffer.
Assessment of immunohistochemical staining
Immunostained tissue arrays were scored semiquantitatively
by two specialist observers without knowledge of the clinical
and pathologic parameters of patients, and in difficult cases, a
consensus was achieved. TMA slides were initially scanned at
low magnification to obtain a general impression of the over-
all distribution of the positive cells and then assessed semi-
quantitatively at higher magnifications, and final scores were
given. The intensity of staining was assigned on a scale of 1 to
3 as 0 (absent), 1 (weak), 2 (moderate), or 3 (strong). The
percentage of positive cells was also assessed semiquantita-
tively. The histochemical score (H-score) was obtained by
multiplying intensity and percentage of positive cells, and a
final score of 0 to 300 was given [33].
Statistical analysis
In order to evaluate the mRNA expression level of Lgr5 and
DCLK1 in tumor tissues compared to normal adjacent mar-
gins, parametric tests including paired t test, one-way
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ANOVA, and Pearson correlation coefficient test were used to
assess significance of differences. Non-parametric tests such
as chi-squared and Spearman’s correlation coefficient test
were used for univariant analysis of immunohistochemistry
(IHC) results. Statistical analysis of data was performed using
IBM SPSS Statistics 22 and a p value of <0.05 was considered
statistically significant.
Results
DCLK1 and Lgr5 mRNA level was increased in CRC
tissues
The mean and standard deviation (SD) of Lgr5 and DCLK1
mRNA expression level in fresh tumor tissues of CRC pa-
tients and adjacent margins were calculated using 2–ΔCt, and
the related fold changes was obtained. For ease of calculation,
decimals up to five digits have been removed. The mean of
Lgr5 mRNA expression level was 983.3 (SD=265.6) in CRC
tumor tissues and 428.5 (SD=186.7) in due margins (Fig. 1).
These data indicates a 2.29-fold change of Lgr5 mRNA ex-
pression in resected tumor tissues compared with normal adja-
cent margins that was statistically significant (p<0.001). In ad-
dition, Lgr5 expression level was significantly higher in patients
at stages III and IV comparing to stages I and II (p=0.02). The
significant higher expression of Lgr5 was also seen in poorly
differentiated tumors (p=0.024). Moreover, the expression level
was significantly higher in patients with the history of preoper-
ative CRT compared to those lacking the neoadjuvant CRT his-
tory (p=0.019). There was no other significant correlation be-
tween the expression level of Lgr5 and other clinicopathologic
findings such as age, sex, tumor location, and tumor size.
The mean expression level of DCLK1 was 165.4 (SD=
66.3) in resected tumor tissues and 50.3 (SD=21.6) in adja-
cent margins (Fig. 1). As a result, a 3.28-fold change was seen
in tumor area compared to related margins that was statistical-
ly significant (p<0.001). The expression level was also sig-
nificantly higher in poorly differentiated tumors (p=0.022)
and in patients at stages III and IV comparing to stages I and
II (p=0.015). In addition, in preoperative CRT-treated pa-
tients, DCLK1 mRNA expression was significantly higher
compared to those lacking the history of CRT (p=0.01). The
correlation between DCLK1 and other clinicopathologic data
was not statistically significant. The correlation of DCLK1
and Lgr5 mRNA expression with patients’ clinicopathologic
findings has been summarized in Table 1.
Pearson’s correlation coefficient test was applied in order to
evaluate the correlation between local DCLK1 and Lgr5
mRNA expression level as well as specify the coloration be-
tween the local and circulating mRNA expression level. The
statistical analysis elucidated a positive correlation between
the mRNA expression level of DCLK1 and Lgr5 in tumor
tissues of CRC patients (r=0.512, p=0.002). Furthermore,
by comparing the level of mRNA expression in tissue samples
with mRNA expression in blood of the same patients from our
previous study [22], it has been revealed that there is a signif-
icant correlation between the mRNA expression level of
DCLK1 in CRC tissue samples (local) with its expression
level in circulation (r=0.602, p=0.001). Similarly, the
mRNA expression level of LGR5 in tissue samples was sig-
nificantly correlated with circulating Lgr5 mRNA level (r=
0.481, p=0.002).
In order to facilitate the comparison of mRNA level be-
tween tumor tissues and normal margins, Youden index was
used to assign a cutoff value for each of two genes. In this
regard, the calculated cutoff for Lgr5 and DCLK1 found to be
759 and 96, respectively.
DCLK1 and Lgr5 protein level was increased in CRC
tissues
A number of 58 paraffin-embedded tissues from CRC pa-
tients were arrayed on TMA blocks and examined by im-
munohistochemistry. Since normal colon and rectum are
known to express DCLK1 and Lgr5, these tissues were
used as positive control. H-score method was used for as-
sessment of expression, and the median H-score was cho-
sen as cutoff value in order to classify the cases as high and
low expressive. Consequently, an H-score of 20 was
assigned as cutoff point for DCLK1, while an H-score of
30 was determined as the cutoff value of Lgr5. In this re-
gard, DCLK1 expression was found to be high in 37 of 58
(63.7 %) tumor tissues (Fig. 2).
The overexpression of DCLK1was significantly correlated
with tumor stage indicating that 72.3 % of stages III and IV
and 27.3% of stages I and II of the CRC patients revealed high
expression (p=0.014). In addition, a positive correlation was
observed between DCLK1 overexpression and tumor grade as
83.3 % of poorly differentiated tumors versus 53.8 % of mod-
erately differentiated and 37.5 % of well-differentiated tumors
have shown high DCLK1 expression comparatively (p=
0.023). Besides, comparison of tumors of patients undergoing
neoadjuvant CRTwith the patients lacking the history of CRT
showed a significant overexpression of DCLK1 in the preop-
erative CRT-treated patient (78.8 %) compared to patient with-
out CRT history (44 %) (p=0.016). No significant correlation
was found between DCLK1 expression and other clinicopath-
ologic parameters including sex, age, tumor location, and
tumor size.
High Lgr5 expression level was also observed in 30 out of
58 (51.7 %) CRC samples (Fig. 2). Similarly, Lgr5 overex-
pression was significantly correlated with tumor stage indicat-
ing 65.9 % of patients with stages III and IV, and 27.2 % of
patients with stages I and II of CRC have shown high Lgr5
expression (p=0.045). Likewise, poorly differentiated tumors
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showed a higher expression of Lgr5 (p=0.028). In this regard,
66.7 % of poorly differentiated, 50 % of moderately differen-
tiated, and 12.5 % of well-differentiated tumors showed Bhigh
expression^ of Lgr5 comparatively. Furthermore, Lgr5 ex-
pression was higher in neoadjuvant CRT-treated patients
(66.6 %) compared to patient with no CRT history (32 %)
(p=0.018). The correlation of Lgr5 expression with other clin-
icopathologic parameters including sex, age, tumor location,
and tumor size was not significant. The correlation of DCLK1
and Lgr5 protein expression with patients’ clinicopathologic
findings has been summarized in Table 2.
Analyzing the results of both CSC markers in paraffin-
embedded tissues of CRC patients using Spearman’s correla-
tion coefficient test have revealed a significant reciprocal
pattern of expression between DCLK1 and Lgr5 (r=0.401,
p=0.006).
Fig. 1 qRT-PCR analysis of DCLK1 and Lgr5 mRNA expression level in CRC patients compared to healthy controls. Data are shown as mean ± SD
Table 1 Correlation of
clinicopathologic findings with
DCLK1 and Lgr5 mRNA
expression showed by p value
Parameter Groups Number (%) DCLK1 (p value) Lgr5 (p value)
Age (years) 20 to 40 9 (15.5) 0.22 0.17
40 to 60 23 (39.7)
≥60 26 (44.8)
Gender Female 27 (46.5) 0.09 0.11
Male 31 (53.5)
Tumor location Colon 34 (58.6) 0.086 0.075
Rectum 24 (41.4)
TNM stage I and II 11 (19) 0.015 0.02
III 28 (48.3)
IV 19 (32.7)
Grade Well differentiated 8 (13.8) 0.022 0.024
Moderately differentiated 26 (44.8)
Poorly differentiated 24 (41.4)
Number of metastatic sites 0 39 (67.2) 0.066 0.13
1 14 (24.2)
≥2 5 (8.6)
Lymphatic invasion Unknown 7 (12.1) 0.082 0.093
No 16 (27.5)
Yes 35 (60.4)
Neoadjuvant history Yes 33 (56.9) 0.01 0.019
No 25 (43.1)
Tumor size <25 mm 32 (55.3) 0.13 0.18
>25 mm 26 (44.8)
p Value of <0.05 was considered statistically significant
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Protein and mRNA expression level of the markers
was significantly correlated
In order to evaluate the correlation trend of protein andmRNA
expression level of the markers, Pearson’s correlation coeffi-
cient test was implemented. The results of correlation analysis
showed a significant positive correlation between DCLK1
protein and mRNA expression level (r=0.674, p<0.001).
Such positive correlation was also observed between Lgr5
protein and mRNA expression level (r=0.670, p<0.001).
Discussion
In spite of recent evidences supporting the role of DCLK1 and
Lgr5 as the most potential colorectal CSC markers [18,
34–36] and their relevance to patient’s clinicopathologic find-
ings [37–40], most studies have focused on investigating
DCLK1 and Lgr5 expression levels solely in tissue or circu-
lation. Amongst, a higher mRNA expression level of DCLK1
and Lgr5 in the blood circulation of CRC patients compared to
tumor-free blood samples was observed in our previous study
[22]. Valladares et al. also reported that the expression pattern
of circulating Lgr5 was correlated with poorer outcome of
CRC patients, metastasis, and high grade of CRC [23].
Despite of the valuable potentiality of CCSC markers in di-
agnostic and prognostic applications, limited number of re-
searches are devoted to investigate CCSC due to the novelty of
this research area and difficulties for CCSC evaluations.
Furthermore, most of these studies have applied PCR method
to evaluate mRNA expression of the circulating markers, instead
of protein assessment which results in more relevant outcomes.
Rationally, CSCs constitute a small subpopulation of tumor cells,
and from this subset, only a small fraction enter the blood stream
which leads to a difficulty in the evaluation of the protein ex-
pression of CCSCmarkers [41]. Nevertheless, higher concentra-
tion of CSCs in tumor tissue makes the protein analysis of CSC
markersmore accessible. Gagliardi et al. evaluatedDCLK1 local
protein expression in tumor tissues of CRC patients and found a
higher expression of DCLK1 in 75 % of primary adenocarci-
nomas providing insight into its potential prognostic capability
[35]. They also demonstrated that 38 % of high-grade tumors
were positive for DCLK1, compared to 0 % of low-grade tu-
mors, which confirms our results. Similar to our study, no sig-
nificant association was found between staining score and tumor
location, tumor size, and morphology. In a study carried out by
Wu et al., the local protein expression of Lgr5 has been assessed
in 192 colorectal carcinoma specimens and revealed a significant
higher Lgr5 expression level in carcinoma compared to normal
mucosa and a positive correlation of Lgr5with histological grade
and TNM stage which resembled our results [38]. Furthermore,
our results showed that local expression of DCLK1 and Lgr5
moves in the same direction at both protein and mRNA level
Fig. 2 aWeak Lgr5
immunoreactivity in normal
colon (H-score=10). b Strong
Lgr5 immunoreactivity in colon
adenocarcinoma (H-score=60). c
Weak DCLK1 immunoreactivity
in normal colon (H-score=5). d
Strong DCLK1 immunoreactivity
in colon adenocarcinoma (H-
score=30) (20× magnification)
Table 2 Correlation of clinicopathologic findings with DCLK1 and
Lgr5 protein expression showed by p value
Parameter DCLK1 (p value) Lgr5 (p value)
Age (years) 0.22 0.27
Gender 0.19 0.17
Tumor location 0.084 0.15
TNM stage 0.014 0.045
Grade 0.023 0.028
Number of metastatic sites 0.12 0.23
Lymphatic invasion 0.09 0.14
Neoadjuvant history 0.016 0.018
Tumor size 0.1 0.083
p Value of <0.05 was considered statistically significant
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which further propose that DCLK1/Lgr5 combination marker
may hold promise as prognostic markers.
In addition to the simultaneous evaluation of local DCLK1
and Lgr5 proteins, which was performed for the first time in
the current study, we also attempted to compare the protein
and mRNA expression level of these markers. A considerable
amount of previous studies about CSC markers have focused
on mRNA evaluation which does not necessarily reflect pro-
tein expression level [42, 43]. In support of this, the assess-
ment of protein and mRNA expression level in tumor tissue
was perused simultaneously in our study to elucidate the pro-
tein and mRNA level of consistency. The observed accor-
dance of protein and mRNA expression level in tumor tissue,
although, may reflect such agreement in blood circulation;
however, further studies are required to delineate the protein
level of circulating CSCmarkers focusing on designing highly
sensitive protein detection assays.
In spite of all revealed positive correlations, some inconsis-
tencies were observed which should be taken into consider-
ation. For example, DCLK1 and Lgr5 mRNA level in some
cases were lower than assigned cutoff point, while in some
controls, their value crossed the cutoff line. In addition, in
some cases, DCLK1 and Lgr5 moved in the opposite direc-
tions which also were observed in some controls (Fig. 3). To
explain such observations, it should be noted that although
DCLK1 and Lgr5 are proposed as the most potential colorec-
tal CSC markers, their expression might be affected by many
other factors including genetic and epigenetic background of
the patients. In addition to person to person heterogeneity,
tumor heterogeneity may also affect the markers’ expression
[44]. Moreover, high expression of the markers in normal
margins may reflect tumor microspread which could be used
as an indicator in tumor monitoring.
Furthermore, in some cases and controls, DCLK1 and Lgr5
protein and mRNA did not correlate with each other (Fig. 3). As
previously mentioned, mRNA expression does not necessarily
convey protein expression. In fact, mRNAmay ormay not trans-
late into protein for many reasons. As an example, microRNAs
(miRNAs) are considered as one of the mRNA degradation fac-
tors which inhibit mRNA to protein translation [45]. Nowadays,
the result of epigenetic-miRNA interaction is considered as a
new layer of complexity in gene regulation which its compre-
hension will open new avenues to understand human
cancerogenesis [46]. Whatever the reason, comprehension of
such inconsistencies depends on future complementary studies.
Surprisingly, no study has been performed to compare the
local and circulating markers’ expression. Based on our hy-
pothesis, comparison of expression level in both tissue and
peripheral blood of same patients would lead to a better un-
derstanding of CSC markers’ expression pattern and provide
valuable insight into future CSC diagnostic and prognostic
implications. Considering CSC ambiguities such as heteroge-
neity and plasticity, as missing pieces of a puzzle, exploring
the position of each piece and its relevance to other parts will
lead to a final configuration of all pieces. In fact, the more
CSC complications get unraveled, the sooner CSCs may enter
into clinical applications. Therefore, in the present study, we
aimed to analyze the DCLK1 and Lgr5 mRNA expression
pattern in tumor tissues of CRC patients in order to compare
the results with our formerly studied mRNA expression of
these markers in blood circulation of same patients [22]. Our
real-time PCR finding showed a higher mRNA expression
level of DCLK1 and Lgr5 in fresh tumor tissues of CRC
patients compared to normal adjacent margins. The overex-
pression of DCLK1 and Lgr5 was correlated positively with
tumor stage and grade. In addition, a positive significant cor-
relationwas observed betweenDCLK1 and Lgr5mRNA level
of CRC tumors. Our current results were in complete accor-
dance with our previous findings, indicating the consistency
of circulating DCLK1/Lgr5 expression with their local
expression.
In line with our previous data in PB, we found that the
mRNA expression level of DCLK1 in CRC patients who re-
ceived preoperative CRT was higher than patients without
history of CRT. Nevertheless, such correlation was not ob-
served between local and circulating Lgr5 expression.
Although the level of mRNA expression of LGR5 in neoad-
juvant CRT-treated tumor tissues was higher than non-treated
patients, such higher expression was not detected in blood
circulation of CRT-treated CRC patients [22].
Enrichment of CSCs after CRT treatment has been reported
in several studies [47–50]. Hypothetically, following the CRT-
imposed shrinkage of tumor bulk and in order to reconstruction
of tumor mass, CSCs activate their self-renewal division capa-
bility as well as differentiation. This transition from quiescence
to activation state leads to the more active CSCs that finally
results in faster reconstruction of tumor mass.More interesting-
ly, some evidences suggest that in CRT-treated tumors, dedif-
ferentiation of non-CSCs to CSCs may be rather high [15]
leading to a more growing CSC population. Such manifesta-
tions provide evidence for CRT-promoting effects on CSC
plasticity and heterogeneity which may result in a new CSC
makeup [51]. Consequently, the observed difference between
local and circulating Lgr5 in CRT-treated patients could be
associated to CRT-induced heterogeneity. CRT inducing effect
on CSC reprogramming has been reported repeatedly [52–54]
giving rise to a new CSC with new combination of markers.
Several additional factors including epithelial-to-
mesenchymal transition (EMT) [55–57], different CSC niche
[58]. and development of CSC metastatic traits [59] may also
lead to different expression of local and circulating CSCmarkers.
Although CSC heterogeneity has always been regarded as
a drawback in CSC investigations, it is of note that from a
different prospective, such diversity may be taken as an ad-
vantage to help tumor victims. In this regard, finding a differ-
ence between local and circulating CSC markers may be
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considered as a privilege to target local and circulating CSC
differently. Based on this model, in order to prevent tumor
metastasis, a circulating CSCmarker could be targeted instead
of local CSC marker. Moreover, we may search for a local
CSC marker in the blood circulation unaware of the fact that
not all local CSC markers also work as circulating CSC
markers. As a result, exploring potential difference in local
and circulating CSC marker expression pattern would be con-
sidered as a valuable aspect of heterogeneity that should be
more explored in future studies.
Regardless of all potential factors evolving CSC heteroge-
neity, the observed difference in local and circulating Lgr5may
be simply explained by Nakanishi’s description of colorectal
CSC. As Nakanishi et al. demonstrated, DCLK1 marks CSCs
Fig. 3 aComparative graph for DCLK1mRNA expression level in CRC
tissues and normal margins. b Comparative graph for Lgr5 mRNA
expression level in CRC tissues and normal margins. c Comparative
graph for DCLK1 mRNA and Pprotein expression level in CRC
tissues. d Comparative graph for Lgr5 mRNA and prorein expression
level in CRC tissues; cutoff line has been drawn to facilitate the
comparison of two values
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and not normal stem cells, while Lgr5 marks both normal and
cancer stem cells. Although Lgr5 accompanies DCLK1 on
colorectal CSCs, evidences suggest that DCLK1 is a more
validated colorectal CSC marker in attribution to tumor
characteristics.
Conclusion
Our analysis revealed a significant positive correlation be-
tween DCLK1 and Lgr5 at both protein and mRNA expres-
sion level. In addition, the mRNA and protein expression of
the markers significantly moved in the same direction. Our
results also showed a similar local and circulating CSC
markers’ mRNA expression pattern, with some minor differ-
ences such as the higher expression of Lgr5 in local but not
circulating CSCs in neoadjuvant CRT-treated CRC patients.
Considering CRT as one of the factors promoting CSC het-
erogeneity, the observed difference in local and circulating
Lgr5 expression in CRT-treated patients might be attributed
to CRT effect. In addition, several other potential factors may
affect the local and circulating CSC markers’ combination
which their effect remains to be clarified in future studies.
Whatever the reason, heterogeneity could be taken as an ad-
vantage to help cancer patients; therefore, the old notion about
the heterogeneity and its complicating nature needs to be
reevaluated.
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